Figure 4

CR3 (OX42) immunoreactivity in striatum. (A-C) Widespread immunoreactivity to complement receptor 3 (CR3) in PBS-infused striatum, Wistar (WIS) MSC-implanted striatum, and ACI MSC-implanted striatum, respectively, in the same rats shown in Fig. 2. (D) The percent area (means ± SEM) of striatum (lesioned side) occupied by CR3 immunoreactivity in the MSC-injected groups (n = 4 – 6) was twice that of PBS-injected controls (n = 5; *p < 0.05). Scale bars = 80 μm.